Clinical trials in crisis

The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency.

Kuntz, RE.
Addressing This Need

To identify and promote practices that will **increase the quality and efficiency of clinical trials**

Public-Private Partnership
Co-Founded by FDA and Duke
involving all stakeholders
70+ members
CTTI Membership
How CTTI Works

- Engage & value all stakeholders equally
- Understand incentives to maintain non-value added activities and have solutions that are mindful of those incentives
- Plant the seeds for change throughout all phases of a project
- Develop actionable, evidence-based, consensus driven recommendations
- Create and share knowledge, tools & resources to facilitate change that improves clinical trials
CTTI Methodology

1. **State Problem**
   - Issue Statement, Project Plan

2. **Gather Evidence**
   - Literature Reviews, Multi-stakeholder Meetings, Surveys, Interviews

3. **Find Solution**
   - Team Meetings, Multi-stakeholder Meetings

4. **Refine Ideas**
   - Team Meetings, Multi-stakeholder Meetings

5. **Identify Research Impediments**
   - Develop Recommendations/Tools

6. **Analyze & Interpret Findings**
   - Workshops, Pilot Studies, Measure Impact

7. **Disseminate & Implement**
Evidence guides the journey to solutions

We use quantitative & qualitative research methods, selecting those best aligned with each project’s objectives, to:

- Identify/describe “what is going on” to gain a better understanding of a particular phenomenon
- Move beyond individual views to a more complete and objective understanding of the disincentives and motivators for change

Equipped with data, we then challenge assumptions, identify roadblocks, build tools and develop recommendations to change the way people think about and conduct clinical trials.
CTTI projects focus on streamlining and accelerating clinical trials, while ensuring the highest standards of quality and human subjects protection. We provide **actionable, evidence-based, consensus-driven** recommendations designed to:

- Accelerate study start-up times & streamline protocols
- Leverage new technologies to improve efficiency of clinical trials
- Enhance the quality of clinical trials without adding undue burden
- Identify streamlined strategies to meet regulatory requirements
# Portfolio of CTTI Projects

<table>
<thead>
<tr>
<th>Completed projects</th>
<th>Investigational plan</th>
<th>Study start-up</th>
<th>Study conduct</th>
<th>Analysis and dissemination</th>
<th>Specialty areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Large simple trials</td>
<td>• Central IRB</td>
<td>• Adverse event reporting</td>
<td>• Long-term opioid data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Uses of electronic data</td>
<td>• Site metrics</td>
<td>• IND safety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Current projects</th>
<th>Investigational plan</th>
<th>Study start-up</th>
<th>Study conduct</th>
<th>Analysis and dissemination</th>
<th>Specialty areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Patient groups and clinical trials</td>
<td>• Central IRB advancement</td>
<td>• Safety case studies</td>
<td>• Streamlining HABP/VABP trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Pregnancy testing</td>
<td>• GCP training</td>
<td>• IND safety advancement</td>
<td>• Pediatric Antibiotic trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• QbD</td>
<td>• Informed consent</td>
<td></td>
<td>• Unmet need in Antibiotic development</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trials based on registries</strong></td>
<td>• Investigator turnover</td>
<td></td>
<td>• HABP/VABP pilot study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Remote Clinical Trials</td>
<td>• Recruitment and retention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **• Long-term opioid data**
Registry Trials Project Team

**Team Leaders:**
- John Laschinger (FDA/CDRH)
- Theodore Lystig (Medtronic)
- James Tcheng (Duke)

**CTTI Project Managers:**
- Steve Mikita (Patient Advocate)
- Sara Calvert (CTTI)

**Team Members:**
- Lauren McLaughlin (MJFF)
- Chunrong Cheng (FDA/CBER)
- Alan Clucas (Galderma)
- Christopher Dowd (CFF)
- E. Dawn Flick (Celgene)
- Nicolle Gatto (Pfizer)
- Kristen Miller (FDA/CDER)
- Daniel Mines (Merck)
- Jules Mitchel (Target Health)
- Magnus Petersson (AstraZeneca)
- Sunil Rao (Duke)
- Arlene Swern (Celgene)
- Emily Zeitler (Duke)
Thank you.

Sara Calvert
sara.calvert@duke.edu